374 related articles for article (PubMed ID: 27589220)
1. Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.
Feldman CH; Marty FM; Winkelmayer WC; Guan H; Franklin JM; Solomon DH; Costenbader KH; Kim SC
Arthritis Rheumatol; 2017 Feb; 69(2):387-397. PubMed ID: 27589220
[TBL] [Abstract][Full Text] [Related]
2. Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.
Choi MY; Li D; Feldman CH; Yoshida K; Guan H; Kim SC; Everett BM; Costenbader KH
Rheumatology (Oxford); 2021 Aug; 60(8):3789-3798. PubMed ID: 33369672
[TBL] [Abstract][Full Text] [Related]
3. Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.
Feldman CH; Collins J; Zhang Z; Xu C; Subramanian SV; Kawachi I; Solomon DH; Costenbader KH
Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1419-1424. PubMed ID: 30354025
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015
[TBL] [Abstract][Full Text] [Related]
6. Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis.
Tse KC; Tang CS; Lam MF; Yap DY; Chan TM
J Rheumatol; 2009 Jan; 36(1):76-81. PubMed ID: 19004041
[TBL] [Abstract][Full Text] [Related]
7. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.
Lee YH; Woo JH; Choi SJ; Ji JD; Song GG
Lupus; 2010 May; 19(6):703-10. PubMed ID: 20064907
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
Fassbinder T; Saunders U; Mickholz E; Jung E; Becker H; Schlüter B; Jacobi AM
Arthritis Res Ther; 2015 Apr; 17(1):92. PubMed ID: 25890338
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY
J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764
[TBL] [Abstract][Full Text] [Related]
10. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
11. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Mok CC
Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
[TBL] [Abstract][Full Text] [Related]
12. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L
Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.
Houssiau FA; D'Cruz D; Sangle S; Remy P; Vasconcelos C; Petrovic R; Fiehn C; de Ramon Garrido E; Gilboe IM; Tektonidou M; Blockmans D; Ravelingien I; le Guern V; Depresseux G; Guillevin L; Cervera R;
Ann Rheum Dis; 2010 Dec; 69(12):2083-9. PubMed ID: 20833738
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
[TBL] [Abstract][Full Text] [Related]
16. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
17. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
Laskari K; Zintzaras E; Tzioufas AG
Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis.
Zheng JN; Yang QR; Zhu GQ; Pan L; Xia JX; Wang Q
Mod Rheumatol; 2020 Jul; 30(4):687-695. PubMed ID: 31269839
[No Abstract] [Full Text] [Related]
19. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis.
Singh JA; Hossain A; Kotb A; Wells G
BMC Med; 2016 Sep; 14(1):137. PubMed ID: 27623861
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.
Orth T; Peters M; Schlaak JF; Krummenauer F; Wanitschke R; Mayet WJ; Galle PR; Neurath MF
Am J Gastroenterol; 2000 May; 95(5):1201-7. PubMed ID: 10811328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]